Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14739MR)

This product GTTS-WQ14739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14739MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13256MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ15500MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ1032MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ6736MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ7080MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ4273MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ12085MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ95MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1121B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW